| Naslov: | Impaired booster-induced SARS-CoV-2 antibody responses in rituximab-treated B-cell lymphoma patients despite peripheral B-Cell Recovery |
|---|
| Avtorji: | ID Jurca, Tomaž (Avtor)
ID Boltežar, Lučka (Avtor)
ID Oražem, Miha (Avtor)
ID Fujs Komloš, Kristina (Avtor)
ID Pohar, Katka (Avtor)
ID Jevnikar, Sara (Avtor)
ID Poljak, Mario (Avtor)
ID Mlakar-Mastnak, Denis (Avtor)
ID Rotovnik-Kozjek, Nada (Avtor)
ID Vratanar, Bor (Avtor)
ID Ocvirk, Janja (Avtor)
ID Ihan, Alojz (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (565,04 KB)
MD5: 9F46EB0981FC1713704494301FD8281A
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | Rituximab-treated patients with B-cell lymphoma exhibit profound B-cell depletion and impaired vaccine-induced antibody responses. However, it remains uncertain whether recovery of peripheral B-cell counts after rituximab is sufficient to restore effective humoral immunity following booster vaccination. Patients and methods In this prospective, single-center observational study at the Institute of Oncology Ljubljana, adult B-cell lymphoma patients treated with or previously exposed to rituximab received the Comirnaty® mRNA COVID-19 vaccine. Antibody responses to the SARS-CoV-2 spike and nucleoprotein were measured at baseline, 14 days after the second dose, and at 3, 6, 9, and 12 months. A third dose was administered at 6 months. T-cell responses (IFN-γ release) were assessed in patients before and after the primary series and booster dose. Lymphocyte subsets were analysed pre-vaccination. Adverse events and nutritional status were monitored. Results Patients undergoing anti-CD20 therapy showed absent antibody responses. Longer intervals since rituximab correlated with peripheral B-cell repopulation. However, even after reaching normal B-cell counts, patients’ antibody responses after revaccination remained significantly lower than in controls. Conclusions Rituximab is associated with impaired vaccine-induced antibody responses. Despite recovery of peripheral B-cell counts, patients with B-cell lymphoma show reduced humoral responses compared with healthy individuals following booster COVID-19 vaccination. |
|---|
| Ključne besede: | lymphoma, B-cell, rituximab, COVID-19 vaccines |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 16.02.2026 |
|---|
| Datum sprejetja članka: | 24.02.2026 |
|---|
| Datum objave: | 24.03.2026 |
|---|
| Kraj izida: | Ljubljana |
|---|
| Založnik: | Association of Radiology and Oncology |
|---|
| Leto izida: | 2026 |
|---|
| Št. strani: | str. 76-85 |
|---|
| Številčenje: | Vol. 60, no. 1 |
|---|
| Izvor: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-29699  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 1318-2099 |
|---|
| COBISS.SI-ID: | 276354563 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Datum objave v DiRROS: | 03.06.2026 |
|---|
| Število ogledov: | 132 |
|---|
| Število prenosov: | 44 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
